ProQR Therapeutics N.V. (PRQR) Form 424B5 — Jun 25, 2026
ProQR Therapeutics is raising capital through a public offering of 27.6 million ordinary shares priced at $1.81 per share, aiming to generate gross proceeds of $50 million. Concurrently, the company entered into a private placement to sell an additional 5.1 million shares to Eli Lilly and Company at the same price to maintain the investor's pro rata ownership, bringing the total shares sold in the transaction to approximately 32.7 million.
Key figures
- Total Debt
- €15,733,000
- Cash Position
- €81,088,000
- Gross Proceeds
- $50,000,001
- Offering Price
- $1.81
- Shares Offered
- 27,624,310
- Total shares sold
- 32,725,090
- Private shares sold
- 5,100,780
- Shelf capacity total
- $300,000,000
- Dilution per share usd
- $1.11
- Total net proceeds estimate
- $55.8 million
Price after filing
1 day: 0.0%7 days: +15.7%30 days: +14.4%
Close on the filing date to close N calendar days later (from $1.56). Historical, not a forecast.
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.